National Anaemia Day: When should anaemia patients consider a bone marrow transplant?

Anaemia remains a pressing public health issue in India mainly due to iron deficiency which hampers cognitive and motor development in children and reduces work capacity in adults.

Pregnant women with anaemia face increased risks of complications such as perinatal loss, prematurity and low birth weight infants. While dietary adjustments and supplements can help manage mild to moderate cases, severe forms of anaemia may require advanced treatments including a bone marrow transplant (BMT).

Firstpost spoke to Dr Rahul Bhargava, the principal director and chief BMT, Fortis Memorial Research Institute, Gurugram, to explain various aspects of the disease.

Anaemia and role of bone marrow transplants

Anaemia is a common disorder characterised by insufficient production or dysfunctional red blood cells. While many cases can be addressed through lifestyle changes, dietary modifications, supplements, or medication, severe forms may necessitate more advanced treatments, says Dr Bhargava.

In certain situations, a bone marrow transplant (BMT) may be the best or only option. However, determining when to consider BMT depends on the underlying cause and severity of the condition, he said.

More from Health

Weight-loss drug Mounjaro in India: Is it better than Ozempic? 'No care for nationhood': Why Ukraine doesn't trust Russia in ceasefire talks, security expert explains

Conditions that may require BMT

Bone marrow transplants are typically reserved for individuals with severe, life-threatening conditions that impair the bone marrow’s ability to produce healthy blood cells. Key conditions include:

Aplastic Anaemia: It is a rare disorder where the bone marrow fails to produce enough blood cells, leading to extreme fatigue, frequent infections, and uncontrolled bleeding. If traditional treatments like immunosuppressive therapy or blood transfusions fail, BMT may be necessary.

Sickle Cell Anaemia: A genetic disorder causing misshapen and sticky red blood cells, leading to blood vessel blockages, severe pain, and organ damage. While medications and transfusions can manage symptoms, BMT is the only known cure, often recommended for children or young adults with severe complications.

Thalassemia Major: An inherited condition causing defective hemoglobin production, leading to severe anaemia and requiring regular blood transfusions. Over time, transfusions can cause iron overload and organ damage. BMT, ideally performed at a young age, can offer a permanent cure.

Impact Shorts

More Shorts

The new human organ scientists discovered in 2020 can help fight cancer of head and neck: Research

Doctor Explains | Why Pap smears can’t detect ovarian cancer and which tests women should rely on instead

Myelodysplastic Syndromes (MDS): A group of disorders where the bone marrow produces abnormal blood cells, which can progress to leukaemia. For high-risk MDS patients unresponsive to other treatments, BMT may be the best option to prevent disease progression.

Risks, considerations and way forward

The decision to undergo a bone marrow transplant depends on several factors, including the severity of the condition, the patient’s overall health, the availability of a suitable donor, and potential risks.

The procedure involves high-dose chemotherapy or radiation to destroy the diseased bone marrow, followed by the transplantation of healthy stem cells from a donor. While BMT can be life-saving, it carries significant risks, such as infections, graft-versus-host disease (GVHD), and complications from pre-transplant treatments, Dr Bhargava said.

Ultimately, the decision to pursue BMT should be made in consultation with a haematologist or transplant specialist, who will evaluate the risks and benefits based on the patient’s medical history and the progression of their anaemia, he said.

For individuals with severe, treatment-resistant anaemia caused by conditions like aplastic anemia, sickle cell disease, or thalassemia, BMT offers hope for a healthier future, Dr Bhargava said.